M72 TB Vaccine Partnership between Serum Institute and Gates MRI marks a major step in tuberculosis prevention. Learn about the new TB vaccine, global health impact, and important exam facts for UPSC, SSC, Banking, Railways and other competitive exams.
India Strengthens Its Leadership in Global Vaccine Manufacturing
India has once again reinforced its position as the world’s vaccine manufacturing hub after the Serum Institute of India (SII) entered into a strategic partnership with the Gates Medical Research Institute (Gates MRI) to manufacture the promising M72/AS01E tuberculosis (TB) vaccine candidate. The agreement aims to ensure large-scale production of the vaccine if it successfully completes Phase III clinical trials and receives regulatory approval.
What is the M72/AS01E TB Vaccine?
M72/AS01E is an investigational vaccine developed to prevent pulmonary tuberculosis in adolescents and adults. Unlike the Bacille Calmette-Guérin (BCG) vaccine, which mainly protects young children against severe forms of TB, M72/AS01E is specifically designed to protect older age groups that account for the majority of TB transmission worldwide.
The vaccine candidate was originally developed by GSK. In 2020, the Gates Medical Research Institute obtained the license to continue its development and is now conducting late-stage clinical trials with support from the Gates Foundation and Wellcome.
Role of the Serum Institute of India
The Serum Institute of India, headquartered in Pune, is the world’s largest vaccine manufacturer by volume. Under the new agreement, SII will receive technology transfer from Gates MRI and prepare manufacturing facilities capable of producing millions of vaccine doses annually.
Reports indicate that the institute plans to invest more than 100 million US dollars in expanding manufacturing capacity to ensure rapid production once regulatory approval is granted. GSK will continue supplying the AS01E adjuvant, a critical component of the vaccine formulation.
Why Tuberculosis Remains a Global Challenge
Tuberculosis continues to be one of the world’s deadliest infectious diseases. According to global estimates, nearly 11 million people developed TB in 2024, while over 1.2 million people died due to the disease. India carries the highest burden of tuberculosis globally, making new preventive tools a national and international priority.
Experts believe that if M72/AS01E proves successful, it could become the first new TB vaccine introduced in more than a century and significantly reduce infections and deaths worldwide.
Significance for India
The partnership demonstrates India’s growing role in global public health and vaccine innovation. It also supports the country’s commitment to eliminating tuberculosis under the National TB Elimination Programme (NTEP).
Affordable manufacturing by the Serum Institute is expected to improve vaccine accessibility in low- and middle-income countries, where TB remains a major health burden. This collaboration aligns with global efforts to achieve the Sustainable Development Goal of ending the TB epidemic.
Conclusion
The collaboration between the Serum Institute of India and Gates MRI marks an important milestone in global healthcare. If the M72/AS01E vaccine successfully completes clinical trials, it could revolutionize tuberculosis prevention, save millions of lives, and further establish India’s leadership in affordable vaccine manufacturing.
B. Why this News is Important
Important for Health and Science Current Affairs
This development is highly significant because tuberculosis continues to be one of the leading infectious diseases worldwide. Government examinations frequently include questions on major vaccine developments, public health initiatives, and international collaborations in healthcare.
Important for India
India accounts for the highest number of TB cases globally. The partnership involving the Serum Institute of India highlights India’s contribution to global vaccine production and its commitment to achieving the national goal of eliminating tuberculosis.
Important for International Cooperation
The agreement represents collaboration between an Indian vaccine manufacturer, an international non-profit research institute, philanthropic organizations such as the Gates Foundation and Wellcome, and pharmaceutical company GSK. Such partnerships demonstrate how international cooperation can accelerate medical innovation and improve global health equity.
Important for Government Exams
Students preparing for UPSC, State PSCs, SSC, Banking, Railways, Defence, and Teaching examinations should remember:
- M72/AS01E is a TB vaccine candidate.
- Serum Institute of India will manufacture the vaccine if approved.
- Gates MRI is leading late-stage development.
- GSK supplies the vaccine adjuvant.
- TB remains one of the world’s deadliest infectious diseases.
These facts are relevant for Science & Technology, Health, International Relations, and Current Affairs sections.
C. Historical Context
Tuberculosis: A Century-Old Public Health Challenge
Tuberculosis has affected humanity for thousands of years and remains one of the oldest known infectious diseases. The BCG vaccine, introduced in 1921, has been the only licensed TB vaccine for over 100 years. Although effective in preventing severe childhood TB, it offers limited protection against pulmonary TB in adults.
The search for a more effective vaccine has continued for decades. M72/AS01E emerged as one of the most promising vaccine candidates after encouraging Phase II trial results. In 2020, Gates MRI licensed the vaccine from GSK and initiated extensive preparations for Phase III clinical trials.
The collaboration with the Serum Institute ensures that manufacturing infrastructure will already be in place if regulatory approval is granted, enabling faster global distribution of the vaccine.
D. Key Takeaways from Serum Institute-Gates MRI TB Vaccine Partnership
| S. No. | Key Takeaway |
|---|---|
| 1 | Serum Institute of India will manufacture the M72/AS01E TB vaccine if approved. |
| 2 | Gates Medical Research Institute is leading the vaccine’s late-stage development. |
| 3 | M72/AS01E could become the first new tuberculosis vaccine in more than 100 years. |
| 4 | Serum Institute plans to invest over US$100 million in manufacturing capacity. |
| 5 | The partnership aims to ensure affordable and large-scale vaccine access for countries with high TB burden. |
Frequently Asked Questions (FAQs) on Serum Institute–Gates MRI M72 TB Vaccine Partnership
1. What is the M72/AS01E vaccine?
The M72/AS01E vaccine is an investigational tuberculosis (TB) vaccine candidate designed to prevent pulmonary tuberculosis, especially among adolescents and adults. It is considered one of the most promising TB vaccine candidates currently under development.
2. Which Indian company will manufacture the M72 TB vaccine?
The Serum Institute of India (SII) will manufacture the M72/AS01E tuberculosis vaccine under its partnership with the Gates Medical Research Institute (Gates MRI), subject to successful completion of clinical trials and regulatory approvals.
3. What is the role of the Gates Medical Research Institute in this partnership?
The Gates Medical Research Institute is responsible for advancing the development of the M72/AS01E vaccine candidate, including conducting late-stage clinical trials and preparing for global access.
4. What is the significance of the M72 TB vaccine?
The M72 TB vaccine is important because it could become the first new tuberculosis vaccine introduced in more than a century. It may provide better protection against pulmonary TB among adults compared to the existing BCG vaccine.
5. Which vaccine is currently available for tuberculosis prevention?
The Bacille Calmette-Guérin (BCG) vaccine is currently the only widely used licensed TB vaccine. It was introduced in 1921 and mainly protects children from severe forms of tuberculosis.
6. Why is tuberculosis considered a major global health challenge?
Tuberculosis remains one of the world’s deadliest infectious diseases. Millions of people are infected every year, and the disease causes significant deaths, particularly in low- and middle-income countries.
7. Which organization developed the original M72/AS01E vaccine candidate?
The M72/AS01E vaccine candidate was originally developed by GlaxoSmithKline (GSK). Later, the Gates Medical Research Institute acquired rights to continue its development.
8. Where is the headquarters of the Serum Institute of India located?
The headquarters of the Serum Institute of India is located in Pune, Maharashtra.
9. What is the National TB Elimination Programme (NTEP)?
The National TB Elimination Programme (NTEP) is an initiative of the Government of India aimed at eliminating tuberculosis from the country by strengthening diagnosis, treatment, prevention, and awareness activities.
10. Why is this partnership important for India?
This partnership highlights India’s role as a global vaccine manufacturing centre and can improve access to affordable TB vaccines in countries with a high burden of tuberculosis.
Some Important Current Affairs Links
